Drug · CHEMBL1237
Comparisons in its trials23
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 23
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Combination of ARB and ACEI vs Monotherapy ARB: A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73m*m in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73m*m, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death | 132 of 724 | 152 of 724 | 1,448 | NCT00555217 | Trial comparisons |
Combination of ARB and ACEI vs Monotherapy ARB: A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD. | 77 of 724 | 101 of 724 | 1,448 | NCT00555217 | Trial comparisons |
| Combination of ARB and ACEI vs Monotherapy ARB: serious adverse events | 416 of 724 | 380 of 724 | 1,448 | NCT00555217 | Trial comparisons |
| ACE-I + Placebo vs ACE-I + ARB: serious adverse events | 88 of 242 | 88 of 244 | 486 | NCT01885559 | Trial comparisons |
| ACE-I + Placebo vs ACE-I + ARB: Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death. | 116 of 242 | 115 of 243 | 485 | NCT01885559 | Trial comparisons |
| Guided by NT-proBNP vs Not Guided by NT-proBNP: Discontinuations | 8 of 127 | 6 of 125 | 252 | NCT00391846 | Trial comparisons |
| Guided by NT-proBNP vs Not Guided by NT-proBNP: serious adverse events | 46 of 127 | 41 of 125 | 252 | NCT00391846 | Trial comparisons |
| Guided by NT-proBNP vs Not Guided by NT-proBNP: Number of CV Deaths | 4 of 123 | 5 of 123 | 246 | NCT00391846 | Trial comparisons |
| Atenolol vs Lisinopril: serious adverse events | 58 of 100 | 70 of 100 | 200 | NCT00582114 | Trial comparisons |
| Treatment vs Control: Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism | 10 of 103 | 2 of 95 | 198 | NCT01837069 | Trial comparisons |
| Treatment vs Control: deaths from any cause | 0 of 103 | 0 of 95 | 198 | NCT01837069 | Trial comparisons |
| Treatment vs Control: serious adverse events | 0 of 103 | 0 of 95 | 198 | NCT01837069 | Trial comparisons |
| Candesartan vs Lisinopril: deaths from any cause | 0 of 87 | 0 of 89 | 176 | NCT01984164 | Trial comparisons |
| Candesartan vs Lisinopril: serious adverse events | 0 of 87 | 0 of 89 | 176 | NCT01984164 | Trial comparisons |
| Intervention vs Control: serious adverse events | 0 of 49 | 0 of 50 | 99 | NCT00661895 | Trial comparisons |
| Events Reported During Treatment With Lisinopril vs Events Reported During Treatment With Placebo: serious adverse events | 0 of 33 | 0 of 33 | 66 | NCT01409837 | Trial comparisons |
| NICHE Method vs Usual Care: deaths from any cause | 0 of 23 | 0 of 26 | 49 | NCT03461003 | Trial comparisons |
| NICHE Method vs Usual Care: serious adverse events | 0 of 23 | 0 of 26 | 49 | NCT03461003 | Trial comparisons |
| NICHE Method vs Usual Care: Number of Participants Who Self-reported Adherence to Intervention | 5 of 15 | 6 of 23 | 38 | NCT03461003 | Trial comparisons |
| Group B (Lisinopril First, Then Placebo) vs Group A (Placebo First, Then Lisinopril): Adverse Events Monitoring | 0 of 17 | 0 of 16 | 33 | NCT01409837 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1237/comparisons